X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (64) 64
index medicus (60) 60
chemistry (56) 56
humans (56) 56
metallurgy (56) 56
male (53) 53
aged (50) 50
female (49) 49
adhesives (42) 42
dyes (42) 42
miscellaneous applications of materials (42) 42
miscellaneous compositions (42) 42
natural resins (42) 42
paints (42) 42
polishes (42) 42
chemical paint or ink removers (41) 41
coating compositions, e.g. paints, varnishes orlacquers (41) 41
correcting fluids (41) 41
filling pastes (41) 41
inks (41) 41
pastes or solids for colouring or printing (41) 41
use of materials therefor (41) 41
woodstains (41) 41
middle aged (40) 40
chemotherapy (37) 37
lung neoplasms - drug therapy (37) 37
lakes (33) 33
mordants (33) 33
organic dyes or closely-related compounds for producing dyes (33) 33
carcinoma, non-small-cell lung - drug therapy (30) 30
cancer (25) 25
lung cancer, non-small cell (24) 24
lung neoplasms - pathology (24) 24
adult (23) 23
treatment outcome (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
respiratory system (21) 21
aged, 80 and over (20) 20
apparatus therefor (19) 19
non-small cell lung cancer (19) 19
care and treatment (18) 18
lung cancer (18) 18
electricity (17) 17
research (17) 17
carboplatin (15) 15
lung neoplasms - mortality (15) 15
physics (15) 15
antineoplastic combined chemotherapy protocols - adverse effects (14) 14
cisplatin (14) 14
disease-free survival (14) 14
after-treatment of single crystals or a homogeneouspolycrystalline material with defined structure (13) 13
basic electric elements (13) 13
carcinoma, non-small-cell lung - pathology (13) 13
chemical surface treatment (13) 13
coating by vacuum evaporation, by sputtering, by ion implantationor by chemical vapour deposition, in general (13) 13
coating by vacuum evaporation, by sputtering, by ionimplantation or by chemical vapour deposition, in general (13) 13
coating material with metallic material (13) 13
coating metallic material (13) 13
crystal growth (13) 13
diffusion treatment of metallic material (13) 13
docetaxel (13) 13
electric solid state devices not otherwise provided for (13) 13
gefitinib (13) 13
inhibiting corrosion of metallic material or incrustation ingeneral (13) 13
production of a homogeneous polycrystalline material withdefined structure (13) 13
refining by zone-melting of material (13) 13
semiconductor devices (13) 13
single crystals or homogeneous polycrystalline material withdefined structure (13) 13
single-crystal-growth (13) 13
surface treatment of metallic material by diffusion into thesurface, by chemical conversion or substitution (13) 13
unidirectional solidification of eutectic material orunidirectional demixing of eutectoid material (13) 13
hematology, oncology and palliative medicine (12) 12
medicine & public health (12) 12
neoplasm staging (12) 12
open-label (12) 12
analysis (11) 11
antineoplastic agents - therapeutic use (11) 11
carcinoma, non-small-cell lung - mortality (11) 11
clinical trials (11) 11
general tagging of cross-sectional technologies spanning over several sections of the ipc (11) 11
general tagging of new technological developments (11) 11
performing operations (11) 11
survival rate (11) 11
technical subjects covered by former us classification (11) 11
technical subjects covered by former uspc (11) 11
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (11) 11
therapy (11) 11
transporting (11) 11
blasting (10) 10
heating (10) 10
lighting (10) 10
mechanical engineering (10) 10
multicenter (10) 10
pulmonary/respiratory (10) 10
weapons (10) 10
antineoplastic agents - adverse effects (9) 9
colour printing (9) 9
erlotinib (9) 9
follow-up studies (9) 9
health aspects (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 24, pp. 2288 - 2301
The addition of atezolizumab (anti–PD-L1 antibody) to a platinum-based chemotherapy regimen improved progression-free survival among patients who had not... 
PHASE-III TRIAL | CELLS | MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | BEVACIZUMAB | ANTIBODY | OPEN-LABEL | CANCER | DOCETAXEL | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Neoplasm Metastasis - drug therapy | Immunotherapy | Female | Paclitaxel - administration & dosage | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Carboplatin - administration & dosage | Carcinoma, Non-Small-Cell Lung - mortality | Genes, erbB-1 | B7-H1 Antigen - antagonists & inhibitors | Receptor Protein-Tyrosine Kinases - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Lung cancer, Non-small cell | Drug therapy | Research | Epidermal growth factor receptors | Liver | Oncology | Lymphocytes T | Metastasis | Cancer therapies | Patients | Bevacizumab | Metastases | Immunosuppression | Chemotherapy | Motivation | Medical prognosis | PD-L1 protein | Paclitaxel | Carboplatin | Population | Death | Vascular endothelial growth factor | Genotypes | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Nihon Naika Gakkai Zasshi, ISSN 0021-5384, 06/2017, Volume 106, Issue 6, pp. 1108 - 1116
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2016, Volume 5, Issue 1, pp. 42 - 50
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 08/2015, Volume 42, Issue 8, pp. 944 - 951
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2010, Volume 28, Issue 20, pp. 3299 - 3306
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 9, pp. 841 - 849
Purpose The AURA study (ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naive patients to examine clinical activity and safety of... 
TYROSINE KINASE INHIBITORS | SURVIVAL | MULTICENTER | GEFITINIB | THERAPY | ONCOLOGY | ACQUIRED-RESISTANCE | OPEN-LABEL | AFATINIB | AZD9291 | ERLOTINIB
Journal Article
Cancer Science, ISSN 1347-9032, 05/2017, Volume 108, Issue 5, pp. 1000 - 1006
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2017, Volume 28, Issue suppl_9
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2015, Volume 33, Issue 1, pp. 194 - 200
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2018, Volume 36, Issue 4, pp. 667 - 673
Journal Article